CORRECTION article

Front. Oncol., 23 April 2025

Sec. Molecular and Cellular Oncology

Volume 15 - 2025 | https://doi.org/10.3389/fonc.2025.1607882

Corrigendum: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC

  • 1. Translational Radiobiology, Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

  • 2. Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

  • 3. Comprehensive Cancer Center Erlangen-Europäische Metropolregion Nürnberg (EMN), Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

  • 4. Division of Molecular Immunology, Internal Medicine III, University Hospital Erlangen, Nikolaus-Fiebiger Center, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany

  • 5. Deutsches Zentrum Immuntherapie, Uniklinikum Erlangen, Erlangen, Germany

  • 6. FAU Profile Center Immunomedicine Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

In the published article, there was an error in the Funding statement. In the Funding statement one sentence was missing. The correct Funding statement appears below.

“The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the DFG Doctoral Training Group 2599 “Fine-Tuners of the Adaptive Immune Response” and partly by the Interdisciplinary Center for Clinical Research (IZKF) in Erlangen. The present work was performed by Julia Meidenbauer in (partial) fulfilment of the requirements for obtaining the degree “Dr. med.” at the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

HNSCC, DNA damage repair, kinase inhibitors, immunomodulation, ATM inhibition, ATR inhibition

Citation

Meidenbauer J, Wachter M, Schulz SR, Mostafa N, Zülch L, Frey B, Fietkau R, Gaipl US and Jost T (2025) Corrigendum: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC. Front. Oncol. 15:1607882. doi: 10.3389/fonc.2025.1607882

Received

08 April 2025

Accepted

09 April 2025

Published

23 April 2025

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

15 - 2025

Updates

Copyright

*Correspondence: Tina Jost,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics